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Activation of the epidermal growth factor receptor (EGFR) pathway has been implicated in tumorigenesis
in non-small cell lung cancer (NSCLC), the most common type of lung cancer. As a result, EGFR has
become a key focus for the development of personalized therapy, with several molecular biomarkers hav-
ing been investigated as potential predictors of response with EGFR tyrosine kinase inhibitors (TKIs) in
NSCLC (e.g., EGFR expression, EGFR gene copy gain, and EGFR mutations). Of these, activating mutations
in EGFR have thus far given the most consistent results based on the available evidence from preclinical
studies and clinical trials. In an attempt to identify patients who are most likely to beneﬁt from treatment
with EGFR TKIs, EGFR mutation testing is being increasingly utilized in clinical practice. Currently in the
United States, no EGFR TKI or accompanying mutational test is approved for the identiﬁcation and ﬁrst-
line treatment of patients with advanced NSCLC. However, the ﬁrst-generation EGFR TKIs, erlotinib and
geﬁtinib, as well as investigational ErbB family TKIs and EGFR mutation testing methods are being eval-
uated in this setting. This review will discuss EGFR mutation testing as a biomarker of response to EGFR
TKIs and the evolution of EGFR mutational analysis in NSCLC. Completed and ongoing clinical trials eval-
uating currently available or investigational EGFR TKIs as ﬁrst-line therapy in molecularly and clinically
selected patients with NSCLC, with a focus on trials in patients whose tumors have EGFR mutations, will
also be reviewed.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Lung cancer is the leading cause of cancer-related mortality for
both men and women in the United States.1 Non-small cell lung
cancer (NSCLC) accounts for more than 85% of lung cancer cases,
of which adenocarcinoma (40%) is the most common subtype, fol-
lowed by squamous cell carcinoma (25%) and large cell carcinoma(10%).2 Only approximately 15% of patients with lung cancer pres-
ent with localized disease. For those NSCLC patients with more ad-
vanced disease, conventional systemic chemotherapy (e.g.,
platinum-based chemotherapy) has been a cornerstone of treat-
ment; however, it provides only a modest beneﬁt in survival.1,3
Not surprisingly, the overall 5-year survival rate for all stages of
NSCLC is only 17%.1
The discovery of epidermal growth factor receptor (EGFR) tyro-
sine kinase inhibitors (TKIs) has led to a new paradigm of lung can-
cer treatment. The use of EGFR TKIs for NSCLC began in 2003. In the
United States, EGFR TKIs were ﬁrst administered to non-selected
patients with advanced NSCLC who had failed all approved chemo-
therapies.4 Remarkably, some of these individuals, particularly
those with adenocarcinoma of the lung, experienced profound
and durable antitumor responses.5,6 As the clinical development
of EGFR TKIs progressed through large-scale global clinical trials,
certain clinical characteristics, including adenocarcinoma histol-
ogy, female gender, non-smoking history, and Asian ethnicity, were
also associated with increased response to EGFR TKIs.7–11 Molecu-
lar predictors, thought to be more inclusive and reliable than
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beneﬁt most from treatment with EGFR TKIs. Several molecular
biomarkers, including gene mutations, protein expression, and
gene copy number, have been identiﬁed. In 2004, initial reports
of somatic EGFR gene mutational analysis in NSCLC patients
responding to EGFR TKIs seemed most promising.7,12
Subsequently, the role of these molecular biomarkers as predic-
tive and prognostic factors has been investigated in NSCLC patients
treated with EGFR TKIs. On the basis of available evidence thus far,
the most reliable predictors of EGFR TKI sensitivity and progres-
sion-free survival (PFS) are tumor EGFR-activating gene muta-
tions.9,10,13–15 As a result of these ﬁndings, EGFR TKIs have been
approved by the European Commission and Asian authorities as
initial therapy for patients with tumor EGFR-activating gene muta-
tions.16,17 As of yet, there has been no US Food and Drug Adminis-
tration (FDA) approval of an EGFR TKI in conjunction with an EGFR
mutation detection method for the ﬁrst-line treatment of patients
with advanced NSCLC.
This article will review the importance of somatic EGFR activat-
ing gene mutations as predictors of response and clinical outcomes
with EGFR-TKI therapy and the current and evolving detection
methods for EGFR mutation analysis employed in clinical trials
and in clinical practice, and ﬁnally summarize the clinical results
of the currently available EGFR TKIs and ongoing clinical trials of
investigational EGFR TKIs in molecularly selected NSCLC patients
with EGFR-activating mutations.Overview of EGFR biology
EGFR, also known as human epidermal growth factor receptor-1
(HER-1), is 1 of the 4 members of the ErbB family of receptor tyro-
sine kinases. It is a multiple domain glycoprotein (170 kilodaltons)
that consists of an extracellular ligand-binding domain and an
intracellular tyrosine kinase domain separated by a transmem-
brane region.18 When endogenous ligands, such as epidermal
growth factor (EGF), transforming growth factor-a (TGF-a), amphi-
regulin, heparin-binding EGF, or betacellulin, bind to EGFR, recep-
tor homodimerization or heterodimerization occurs at the cell
surface and eventually leads to internalization of the dimerized
receptor.18,19 The receptor dimerization results in autophosphory-
lation of the intracytoplasmic EGFR tyrosine kinase domain.20 Sub-
sequently, the phosphorylated tyrosine kinase stimulates an
intracellular signal transduction cascade through several down-
stream pathways, including the retrovirus-associated DNA se-
quences (RAS)/v-raf 1 murine leukemia viral oncogene homolog
1 (RAF)/mitogen-activated protein kinase kinase (MEK)/mitogen-
activated protein kinase (MAPK) pathway, phosphoinositide-3-ki-
nase (PI3K)/protein kinase B (AKT) pathway, and Janus tyrosine ki-
nase (JAK)/signal transducers and activators of transcription (STAT)
pathway, which regulate apoptosis and cell proliferation (Fig. 1).21EGFR TKIs
EGFR TKIs are small molecules that act by inhibiting EGFR auto-
phosphorylation and, therefore, receptor activation and signal
transduction. The ﬁrst-generation TKIs, erlotinib and geﬁtinib, are
oral bioavailable synthetic anilinoquinazolines that reversibly bind
with high afﬁnity to the intracellular tyrosine kinase domain of
EGFR competitively inhibiting adenosine-50 triphosphate (ATP)
binding. A new generation of EGFR TKIs possesses new features;
they are active against multiple ErbB family receptor targets and/
or bind the tyrosine kinase domain targets irreversibly.22 Afatinib
(BIBW 2992), dacomitinib (PF00299804), and neratinib (HKI-272)
are investigational ErbB family inhibitors that irreversibly target
EGFR, HER2, and HER4.23–26EGFR mutations as molecular biomarkers
Molecularly targeted therapy has become an exciting area of
lung cancer treatment. The ability to target speciﬁc cancer cell
oncogenic pathways not only improves the efﬁcacy of the treat-
ment, but also may reduce toxicities as compared to conventional
cytotoxic chemotherapy. However, only 6% of unselected patients
with NSCLC respond to EGFR TKIs.5 Therefore, the selection of suit-
able patients that would beneﬁt most from treatment with EGFR
TKIs is crucial. While patients with certain clinical characteristics
respond better to EGFR TKIs, selection of patients by using molec-
ular biomarkers has been found to be more inclusive and reliable.EGFR gene mutations
Somatic EGFR gene mutations were ﬁrst described in 2004 by 3
independent studies after observation of a dramatic response to gef-
itinib in a subset of unselected NSCLC patients in 2 large phase II
clinical trials (IDEAL1 and -2).5–8,12 This subset of patients with an
increased response to EGFR TKIs was found to harbor somatic EGFR
gene mutations in the kinase domain. The most common EGFR
mutations in patients with NSCLC include short in-frame deletions
in exon 19 and a speciﬁc point mutation in exon 21 at codon 858.
Both mutations account for approximately 80–90% of the EGFR
mutations detected (Fig. 2). These activating mutations occur in
the ATP binding cleft of EGFR where EGFR TKIs bind and impart a
sensitivity to small-molecule EGFR TKIs.27,28 Patients found to have
an EGFR exon 19 deletion mutation have signiﬁcantly longer median
survival times (up to 38months) than those with an exon 21 L858R
mutation (up to 17 months) when treated with geﬁtinib or erloti-
nib.14,15,29 There have been more than 20 different exon 19 deletions
identiﬁed in lung adenocarcinomas.30 The most frequent deletions in
exon 19 encompass the amino acid string from L747 through E749
(LRE fragment), and based on data from the Somatic Mutations in
EGFR Database, the most common LRE deletions are delE746-A750
(66.1%), followed by delL747-P753insS (56.8%), delL747-A750insP
(4.0%), and delL747-T751 (3.7%).31,32 delS752-I759 is the most com-
mon non-LRE deletion.32 Among patients with exon 19 deletions,
those with non-LRE deletions had a lower response to EGFR TKIs
compared with those harboring LRE deletions (P = 0.022); however,
overall survival (OS) was not signiﬁcantly different among mutation
position groups (P = 0.776).32 Other less commonly detected sensi-
tizing EGFR mutations include the G719A/C/S and S720F mutations
in exon 18, the L861Q/R mutations in exon 21, and the V765A,
T783A, and S768I mutations in exon 20.28,30,33,34
Activating EGFR mutations are most common in patients with
adenocarcinoma histology, women, never smokers, and those of
Asian ethnicity, which are known clinical predictors for harboring
activating EGFR mutations, and as a result, increased response to
EGFR TKIs.5 The overall response rate (RR) is as high as approxi-
mately 80% in patients harboring EGFR mutations,35 and the prev-
alence of EGFR mutations is approximately 20–40% among Asians
and 10% among Caucasians.9,36,37 Although the initial overall RR
to EGFR TKIs is high for patients with EGFR mutations, almost all
patients subsequently develop acquired resistance within 10–
16 months.38 Acquired resistance to EGFR TKIs is deﬁned as (1)
prior single-agent EGFR TKI (e.g., geﬁtinib, erlotinib) therapy; (2)
either of the following: a tumor that harbors a drug-sensitizing
EGFR mutation, or objective clinical beneﬁt achieved with an EGFR
TKI; (3) systemic disease progression (as deﬁned by Response Eval-
uation Criteria in Solid Tumors [RECIST] or World Health Organiza-
tion [WHO]) while receiving continuous geﬁtinib or erlotinib
within the last 30 days; and (4) no systemic therapy administered
between cessation of geﬁtinib or erlotinib and beginning new
treatment.39
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Fig. 1. The EGFR signaling pathway. Upon ligand binding, EGFR or another ErbB family member dimerizes and is activated through phosphorylation of its intracellular
tyrosine kinase domain. This leads to signal transduction through several downstream pathways that regulate apoptosis and cell proliferation. Abbreviations: EGFR,
epidermal growth factor receptor; ErbB, erythroblastic leukemia viral oncogene homolog; PI3K, phosphoinositide-3-kinase; AKT, protein kinase B; RAS, retrovirus-associated
DNA sequences; RAF, v-raf 1 murine leukemia viral oncogene homolog 1; MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; JAK, Janus
tyrosine kinase; STAT, signal transducers and activators of transcription.
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clude development of a secondary EGFR mutation, ampliﬁcation
of met proto-oncogene (hepatocyte growth factor receptor; MET), or
increased expression of other receptor tyrosine kinases.40 The most
common mutation associated with acquired resistance is T790M, a
secondary point mutation located at exon 20 that results in substi-
tution of methionine for threonine at position 790.30,41 T790M is
associated with over 50% of adenocarcinoma cases with acquired
resistance, and is associated with primary resistance in approxi-
mately 1% of untreated patients.30 This mutation has been shown
to increase the afﬁnity of EGFR for ATP relative to its afﬁnity for
EGFR TKIs.42 Among patients with acquired resistance to EGFR
TKIs, the presence of T790M is associated with a favorable progno-
sis relative to acquired resistance via other processes (median time
to progression, 14 vs 11 months, P = 0.10; OS, 39 vs 26 months,
P = 0.007).38 Other less common mutations associated with EGFR-
TKI resistance include insertion mutation in exon 19 (D761Y),
insertion mutations in exon 20 (D770-N771), and point mutations
in exon 20 (V769L, N771T; Fig. 2).30EGFR mutation detection methods
The discovery of EGFR mutations as a powerful predictive and
prognostic marker for response to EGFR TKIs has led to changesin clinical practice. The detection of somatic EGFR tyrosine kinase
domain mutations at diagnosis in NSCLC has been increasingly uti-
lized to identify patients who are more likely to beneﬁt from EGFR
TKIs. However, as of yet, there is no accepted consensus on which
EGFRmutation method is preferable and no US FDA-approved EGFR
mutation test. In addition, controversy exists regarding which his-
tological subtypes of NSCLC to test for EGFR-activating mutations.
The National Comprehensive Cancer Network (NCCN) recommends
EGFR mutation testing for adenocarcinoma, large cell, and NSCLC
not otherwise speciﬁed (NOS) and no EGFR mutation testing for
squamous cell carcinoma of the lung.3 These recommendations
are in contrast to the American Society of Clinical Oncology (ASCO)
guidelines.43 The ASCO guidelines recommend EGFRmutation test-
ing for advanced NSCLC patients who are being considered for ﬁrst-
line therapy with an EGFR TKI to determine whether an EGFR TKI
or chemotherapy is the appropriate ﬁrst-line therapy. Three differ-
ent techniques for detecting EGFR mutations will be discussed.DNA sequencing
Sanger sequencing of DNA was the earliest and has been the
most widely used technique for identiﬁcation of EGFR mutations.
This type of DNA sequencing is often considered the ‘‘gold stan-
dard’’ for mutation detection technologies. Sequencing involves
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Fig. 2. Frequency of mutations in exons 18–21 of the EGFR gene and the association with responsiveness to EGFR TKIs. Diagram depicting the locations and frequencies of
EGFR gene mutations detected in the tumors of patients with NSCLC. The most common EGFR mutations are exon 19 deletions and exon 21 point mutations at codon 858,
which together account for approximately 80–90% of cases. Reprinted with permission from Macmillan Publishers Ltd: Modern Pathology,30  2012. Abbreviations: EGFR,
epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer.
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merase chain reaction (PCR) ampliﬁcation of speciﬁc gene regions
and subsequent sequencing of the PCR products using dideoxy-
labeled nucleotides.44 The major challenge associated with this
technique is its sensitivity to detect mutant alleles.45,46 Optimal
results are obtained when the percentage of tumor cells in the
sample is 50% or more,44 and standard tumor biopsy samples
frequently do not contain enough high-quality DNA to be useful
for direct sequencing.47 Two novel DNA sequencing methodologies
are being explored: pyrosequencing and massively parallel or next-
generation sequencing (NGS).48,49 Pyrosequencing is a method of
DNA sequencing based on the ‘‘sequencing by synthesis’’ approach
that relies on the detection of pyrophosphate release upon nucleo-
tide incorporation, in contrast to Sanger sequencing, which is
based on chain termination with dideoxynucleotides.49 Although
pyrosequencing is limited to individual DNA sequence in the
neighborhood of 300 to 500 nucleotides, shorter than Sanger
sequencing (which is limited at 800–1000 nucleotides), it is a fast
method with real-time read out.49–52 Massively parallel sequenc-
ing employs several high-throughput DNA sequencing approaches
and is also called NGS or second-generation sequencing.48 These
technologies use miniaturized and parallelized platforms for
sequencing of millions of short nucleotides (50–400 bases).52,53
All NGS platforms have in common a technical paradigm of
massively parallel sequencing via clonally ampliﬁed, spatially
separated DNA templates or single DNA molecules in a ﬂow
cell.48,54 This design is very different from Sanger sequencing,
which uses capillary electrophoretic separation of chain-termina-
tion sequencing of individual reaction products.48 One of the added
advantages of NGS over other molecular technologies is its ability
to rapidly sequence known mutation hotspots in multiple genes atthe same time. This is appealing when selection of therapeutics is
based on the presence or absence of activation (i.e., sensitizing)
mutations and resistance mutations in the same or alternative
genes of a pathway. The ability to sequence multiple hotspots
within the same gene or in different genes is now possible in
clinical laboratories with instruments better designed for this
setting such as the MiSeq from Illumina and the Ion Torrent
Personal Genome Machine (PGM) from Life Technologies.55
PCR-mediated analysis
Many mutation-speciﬁc PCR assays have been used to detect
EGFR mutations. The method is rapid, sensitive, and can be per-
formed using small samples. PCR followed by restriction enzyme
digestion and capillary electrophoresis is one of the simplest ways
to detect the most common activating mutations. Different PCR as-
says are commercially available, including the EGFR29mutation kit
(Qiagen),56,57 peptide nucleic acid-locked nucleic acid (PNA-LNA)
PCR clamp,58–60 denaturing high-performance liquid chromatogra-
phy (HPLC),61,62 MassARRAY System (Sequenom),63 SNaPshot
(Life Technologies),64,65 and competitive allele-speciﬁc TaqMan
PCR (castPCR) (Life Technologies).66
Real-time PCR technology offers the advantage of increased
sensitivity and speciﬁcity when followed by hybridization with
mutation-speciﬁc ﬂuorescent probes,67,68 or high-resolution
melting temperature analysis. In addition, others have used allele-
speciﬁc real-time PCR for the identiﬁcation of speciﬁc point
mutations.
There are several commercially available EGFR mutation kits
from various vendors, none of which have been approved by the
FDA. One such vendor, Qiagen, offers a kit designed to detect the
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type genomic DNA. The test kit uses a PCR-based assay in which
speciﬁc areas of DNA containing mutations are targeted by Ampli-
ﬁcation Refractory Mutation System (ARMS) primers and Scorpions
technology is used to amplify and detect those speciﬁc areas of
DNA.69 Using this kit, a German panel for mutation testing in
NSCLC evaluated the detectability of EGFR mutations compared
to direct sequencing of exons 18–21 in 40 samples of NSCLC. The
panel determined that the kit failed to detect 32% of the EGFR-acti-
vating mutations that had been detected by direct sequencing.56
The sensitivity of this kit is approximately 93%57; however, detec-
tion is limited to those mutations speciﬁcally targeted by the de-
signed primers.
The PNA-LNA PCR clamp system is a PCR assay that is used to
detect mutations occurring at speciﬁc positions, including G719S,
G719C, L858R, L816Q, and 7 different exon 19 deletions; the assay
can be performed in the presence of 100- to 1000-fold wild-type
alleles without the need to remove the contaminating normal
cells.58–60 Therefore, this method can be used to detect EGFRmuta-
tions from samples such as sputum, pleural effusion, and bronchial
washings that often contain many normal cells. The sensitivity and
speciﬁcity of the test has been reported in the range of 97% and
100%, and the test can be completed within 2 h.58,60 This method
was developed by a Japanese group58 and has been increasingly
used in clinical trials conducted in Asia.
The detection of EGFR mutations by denaturing HPLC involves
subjecting PCR products to ion-pair-reverse-phase liquid chroma-
tography. The underlying principle of denaturing HPLC is that par-
tially denatured heteroduplex PCR products containing mutated
sequences will move through the chromatography column at dif-
ferent rates as compared with homoduplex sequences that do
not contain mutations.62 The sensitivity and speciﬁcity of the
method has been reported in the range of 87–100%. In one study,
this method detected 4% of mutations that were not previously de-
tected by direct sequencing.61
Although Sanger sequencing has been most widely used for
EGFRmutation detection, one of the limitations is that it cannot de-
tect EGFR mutations in individuals with approximately 10% allele
frequencies. Conversely, the MassARRAY system (Sequenom) uti-
lizes PCR ampliﬁcation and single-base primer extension for muta-
tion detections, with the ability to detect low abundant and rare
mutations in a heterogenous mixture of cancer and normal tis-
sue.70 Thomas et al. compared the sensitivity of this system to both
Sanger sequencing and a pyrosequencing method for the detection
of EGFR mutations in 22 lung tumor samples. Both mass spectro-
metric genotyping and pyrosequencing detected 12 mutations,
while Sanger sequencing detected only 9 mutations.63 To improve
the speed and accessibility of mutation proﬁling by this system,
Sequenom has offered the OncoCarta™ Panel, a pre-designed mul-
ti-gene panel with 19 oncogenes and 238 mutations.70
The SNaPshot assay (Life Technologies) consists of a multi-
plexed PCR step followed by a single-base extension reaction that
generates allele-speciﬁc ﬂuorescently labeled probes, which are
subsequently analyzed by capillary electrophoresis. It performs
well on formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue samples
and is designed to detect more than 40 types of recurrent genetic
alterations in lung cancer.65 The advantage of this method is that
it utilizes capillary electrophoresis instruments that are present
in many clinical laboratories for Sanger sequencing, and thus sub-
stantial capital expenses can be avoided. Dias-Santagata et al. com-
pared the SNaPshot assay to other platforms.64 While both
SNaPshot assay and Sanger sequencing detect the same muta-
tions, the SNaPshot assay requires 3–6 times less tumor DNA.
The comparison of SNaPshot assay and MassARRAY was some-
what limited due to lack of optimization of the assay. However,
it was concluded that the MassARRAY system is more laborintensive and expensive, and requires more tissue sample than
the SNaPshot assay. A limitation of the SNaPshot assay is the
detection of only point mutations at a speciﬁc site and not ampli-
ﬁcations, insertions, or deletions.65
The TaqMan Mutation Detection Assay is a real-time PCR
method for detection of somatic mutations.66,71 It is powered by
castPCR technology (Life Technologies) that combines allele-spe-
ciﬁc TaqMan qPCR with allele-speciﬁc blockers to suppress ampli-
ﬁcation of the wild-type allele, resulting in better speciﬁcity.71 The
assay is capable of detecting 0.1% mutation in 10,000 copies of
wild-type genomic DNA (gDNA) background.71 Didelot et al. eval-
uated KRAS, BRAF, and EGFR genotyping by this method on subop-
timal FFPE colon and lung cancer samples. Of 63 samples, 60 were
correctly genotyped.66 One major drawback of this method is that
it does not identify the T790M mutant due to reduced sensitivity.
Immunohistochemistry
Immunohistochemistry (IHC) is a widely used method in the
diagnosis of cancer that uses speciﬁc antibodies to bind antigens.
In 2009, Yu et al. ﬁrst developed 2 mutation-speciﬁc rabbit anti-
bodies against E746-A750del and the L858R point mutation and
evaluated them in 340 parafﬁn-embedded NSCLC tumor samples
by Western blotting, immunoﬂuorescence, and IHC. Compared
with direct DNA sequencing, the sensitivity of the IHC assay was
92% with a speciﬁcity of 99%.47 Other studies examined the pres-
ence of EGFRmutations in NSCLC by IHC using the same antibodies
and reported sensitivity ranging from 36%–100% and speciﬁcity
ranging from 92%–100%.72–77 Although these antibodies seem to
be reliable for detection of the most common EGFR mutations,
other uncommon EGFR mutations, as well as the resistance
mutation T790M in exon 20, cannot be detected.77 In addition,
IHC requires a validated standardization process due to multiple
variable factors, including type of antibodies, tissue ﬁxation
methods, and methods of interpretation.33
Summary of EGFR mutation detection methods
In summary, EGFR mutations can be detected using a variety of
methods. The strengths and weaknesses of each method are sum-
marized in Table 1. To date, there is still no universally accepted
consensus or recommendation to facilitate implementation of
standardized testing for EGFR mutations in clinical practice. The
most appropriate testing method for EGFRmutations to predict re-
sponse with EGFR TKIs still needs to be addressed and validated. It
is important to note that EGFR mutation testing for the purpose of
directing therapeutic selection must be performed in a Clinical
Laboratory Improvements Amendments (CLIA)-certiﬁed clinical
laboratory. Thus, different technologies may be more suitable for
this type of environment and FDA clearance/approval may be
warranted.EGFR TKIs as initial therapy in molecularly selected NSCLC
Phase II studies of geﬁtinib in patients with advanced NSCLC
have shown response accompanied by symptomatic improvement
in approximately 10% of unselected patients.5,6 In 2004, somatic
EGFR mutations as predictive molecular biomarkers for response
to EGFR TKIs were noted by 3 landmark studies.7,8,12 Since then,
further clinical trials have been conducted to evaluate efﬁcacy of
EGFR TKIs as ﬁrst-line therapy for NSCLC in both clinically selected
and molecularly selected patients.
One of the pivotal clinical trials that led to the approval of EGFR
TKIs in Europe in the ﬁrst-line setting was the phase III randomized
Iressa Pan-Asia Study (IPASS) that evaluated the efﬁcacy, safety,
Table 1
Pros and Cons of EGFR detection methods.
Method Pros Cons
Sanger or dideoxy
sequencing
 Familiarity, stemming from being the earliest introduced and most widely
used EGFR mutation detection method94
 Requires large amounts of tissue; not feasible
for unresected tumors94
 Expensive and time-consuming94
 Limited sensitivity47; some rare EGFR mutant
alleles typically fall below the detection limit
Next-generation or
massively parallel
sequencing
 Greater depth of coverage, multiple targets simultaneously sequenced, shorter
turn-around time, scalable, cost effective48,49
 Requires new instrumentation and expertise48
 Data analysis is exclusively informatics48
 Validation for multiple genes with many
mutations is costly
 No signiﬁcant guidelines
Immunohistochemistry  Established technique47
 36–100% sensitivity and >90% speciﬁcity47,72–77
 Applicability to a variety of sample types47
 Inability to detect uncommon EGFR mutations
or the resistance mutation T790M77
 Requires a validated standardization process33
PCR-based analysis
Scorpion Ampliﬁcation
Refractory Mutation
System (DS)
 Ability to detect 29 of the most prevalent somatic EGFR mutations, including
rare alleles undetectable by direct sequencing95
 >90% sensitivity57
 Simple and rapid (results within 24 h)96,97
 Applicability to a variety of sample types; allows for non-invasive testing95
 Detection limited to those mutations speciﬁcally
targeted by the designed Scorpions primers96
 May be less cost-effective relative to other
methods97
PNA-LNA PCR clamp  Ability to detect a mutant EGFR sequence in specimens containing 100–1000
excess copies of wild-type EGFR58
 >97% sensitivity and 100% speciﬁcity58,60
 Rapid (may be completed in 40 min) and inexpensive60
 Applicability to a variety of sample types; allows for non-invasive testing59,60
 Potential inability to detect small numbers of
mutants in tumors with heterogeneity for EGFR
mutations60
Denaturing HPLC  Ability to detect a mutant EGFR sequence in specimens containing 1.6–6.25%
mutated DNA62
 Potential 100% sensitivity and >85% speciﬁcity61
 Rapid and cost-effective62
 Applicability to a variety of sample types61,62
 Inability to detect homozygous mutations61,62
MassARRAY  Ability to detect a mutant EGFR sequence in specimens containing 610%
mutated DNA70
 More sensitive than Sanger sequencing63
 High cost of instrument
SNaPshot  Ability to detect a mutant EGFR sequence in specimens containing 610%
mutated DNA64
 Availability of the necessary equipment (PCR machine and capillary
sequencer) in most clinical laboratories98
 Costs 80% less than direct sequencing98
 Inability to detect ampliﬁcations, insertions, or
deletions65
TaqMan mutation
detection assay
 Ability to detect 0.1% mutation in 10,000 copies of wild-type
DNA background71
 Rapid and simple66
 Decreased sensitivity to detect T790M
mutation66
EGFR, epidermal growth factor receptor; PNA-LNA PCR, peptide nucleic acid-locked nucleic acid polymerase chain reaction; HPLC, high-performance liquid chromatography.
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litaxel chemotherapy as ﬁrst-line treatment in 1217 clinically se-
lected East Asian, never or former light smokers with
adenocarcinoma histology.78,79 The 12-month rate of PFS (primary
outcome) was prolonged with geﬁtinib compared with chemother-
apy in the intention-to-treat population (24.9% vs 6.7%; hazard ra-
tio [HR], 0.74; 95% conﬁdence interval [CI], 0.65–0.85; P < 0.001). In
a planned subgroup analysis of patients with EGFR mutations, pro-
longed PFS (HR, 0.48; 95% CI, 0.36–0.64; P < 0.001) and a higher
objective RR (71.2% vs 47.3% with chemotherapy) were noted
among patients who received geﬁtinib.78 Final analysis of OS dem-
onstrated no signiﬁcant beneﬁt for geﬁtinib in the overall popula-
tion (HR, 0.90; 95% CI, 0.79–1.02; P = 0.109) or the EGFR mutation-
positive subgroup (HR, 1.00; 95% CI, 0.76–1.33; P = 0.990).79 Addi-
tional biomarker analyses from the IPASS study, published with the
ﬁnal OS data, showed that EGFR mutations were the strongest pre-
dictive biomarker for PFS and tumor response to ﬁrst-line geﬁti-
nib.79 Geﬁtinib produced signiﬁcantly prolonged PFS among
patients with tumors that exhibited both high EGFR gene copy
number and EGFR mutation (HR, 0.48; 95% CI, 0.34–0.67) but not
high EGFR gene copy number without EGFR mutation, in whom
PFS was signiﬁcantly shorter relative to carboplatin/paclitaxelrecipients (HR, 3.85; 95% CI, 2.09–7.09). Using similar clinically se-
lected patients, the First-line Single agent Iressa vs Gemcitabine
and cisplatin trial in Never-smokers with Adenocarcinoma of the
Lung (First-SIGNAL; N = 313) study revealed similar PFS and OS re-
sults to those of IPASS.80 A number of other phase II and phase III
trials have evaluated the efﬁcacy of EGFR TKIs as ﬁrst-line treat-
ment in molecularly selected advanced NSCLC patients with con-
ﬁrmed EGFR mutations (Table 2).
Geﬁtinib
Geﬁtinib was ﬁrst approved in Europe in 2009 for use in all lines
of treatment for NSCLC patients harboring EGFR mutations but is
not currently approved by the US FDA (application to be with-
drawn in 2011).81 In the phase III NEJ002 trial (N = 230), geﬁtinib
was compared to carboplatin/paclitaxel in advanced NSCLC pa-
tients whose tumors had EGFR mutations. More than 90% of pa-
tients had adenocarcinoma, 63% were women, and all had tested
positive for EGFR-activating mutations with PNA-LNA clamp test-
ing. After a planned interim analysis, this trial was interrupted
due to a signiﬁcantly longer median PFS (10.8 vs 5.4 months; HR,
0.30; P < 0.001) and a higher RR (73.7% vs 30.7%, P < 0.001)
Table 2
Results from phase II and III clinical trials evaluating EGFR TKIs as ﬁrst-line therapy in molecularly selected NSCLC patient populations.
Trial Patient population EGFR mutation
detection methods
Treatment RR % PFS, median OS, median
Geﬁtinib
Phase II, open-label99 Japanese with
EGFR-activating
mutations; N = 30
PNA-LNA PCR
clamp
Geﬁtinib until
disease progression
66% (90% CI,
51–80)
6.5 mo 17.8 mo
Phase II, open-label100 Japanese with
EGFR-activating
mutations; N = 19
PCR and mutation-
allele-speciﬁc
ampliﬁcation
Geﬁtinib until
disease progression
63.2% (95% CI,
38.4–83.7)
7.1 mo 20.0 mo
Phase II, open-label101 Japanese with
EGFR-activating
mutations; N = 15
NR Geﬁtinib until
disease progression
60% (95% CI,
36.0–80.9)
10.4 mo (95% CI,
7.2–13.6)
NR
Phase II, open-label102 Japanese with
EGFR-activating
mutations; N = 54
NR Vinorelbine or
gemcitabine vs
geﬁtinib
19% vs 45% NR 18.9 mo vs
24.4 mo
NEJ003; phase II,
open-label103
Japanese with
EGFR-activating
mutations; N = 31
PNA-LNA PCR
clamp
Geﬁtinib 74% (95% CI,
58–91)
13.6 mo NR
Phase II, open-label104 EGFR-activating
mutations; N = 31
Direct sequencing Geﬁtinib until
disease progression
55% (95% CI,
33–70)
9.2 mo (95% CI,
6.2–11.8)
17.5 mo
(95% CI,
13.5–21.3)
WJTOG3405; phase III,
randomized,
open-label84
Japanese with
EGFR-activating
mutations;
N = 177
Fragment analysis
and the Cycleave
method (with
conﬁrmation by
direct
sequencing), with
protocol
amendment
allowing direct
sequencing, PNA-
LNA PCR clamp, or
PCR invader
Cisplatin/
docetaxel vs
geﬁtinib
32.2% vs 62.1%
(difference, 29.9%;
95% CI, 12.6–47.1;
P < 0.0001)
6.3 mo vs 9.2 mo
(HR, 0.489;
95% CI,
0.336–0.710;
P < 0.0001)
NR
NEJ002; phase III,
randomized82,83
EGFR-activating
mutations;
N = 230
PNA-LNA PCR
clamp
Carboplatin/
paclitaxel vs
geﬁtinib
30.7% vs 73.7%
(P < 0.001)
5.4 mo vs 10.8 mo
(HR, 0.30; 95% CI,
0.22–0.41;
P < 0.001)
26.6 mo vs
27.7 mo (HR,
0.887; 95% CI,
0.634–1.241;
P = 0.483)
Erlotinib
Phase II, open-label105 Caucasian with
EGFR-activating
mutations; N = 46
NR Erlotinib n = 26 44+ wk 56+ wk
OPTIMAL; phase III,
randomized,
open-label86,106
Chinese with
EGFR-activating
mutations;
N = 165
PCR, followed by
direct DNA
sequencing
Carboplatin/
gemcitabine vs
erlotinib
36% vs 83%
(P < 0.0001)
4.6 mo vs 13.1 mo
(HR, 0.16;
P < 0.0001)
NR
EURTAC; phase III,
randomized,
open-label87
European with
EGFR-activating
mutations;
N = 173
Direct sequencing
(with
conﬁrmation with
an independent
technique)
Platinum-based
chemotherapy vs
erlotinib
15% vs 58%
(P < 0.0001)
5.2 mo vs 9.7 mo
(HR, 0.37; 95% CI,
0.25–0.54;
P < 0.0001)
19.5 mo vs
19.3 mo (HR, 1.04;
95% CI, 0.65–1.68;
P = 0.87)
Afatinib
LUX-Lung 3; phase III,
randomized,
open-label89
EGFR-activating
mutations;
N = 345
PCR (Therascreen
EGFR kit)
Cisplatin/
pemetrexed vs
afatinib
23% vs 56%
(P < 0.0001)
6.9 mo vs
11.1 mo
(HR, 0.58; 95% CI,
0.43–0.78;
P = 0.0004)
NR
Dacomitinib
Phase II, open-label92 Non-smokers/
former light
smokers or EGFR-
activating
mutations, with
adenocarcinoma; N = 74
NR Dacomitinib NR 9.30 mo (95% CI,
6.50–11.17)
NR
CI, conﬁdence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NR, not reported; NSCLC, non-small cell lung cancer; OS, overall survival; PCR, polymerase
chain reaction; PFS, progression-free survival; PNA-LNA PCR, peptide nucleic acid-locked nucleic acid polymerase chain reaction; RR, response rate; TKI, tyrosine kinase
inhibitor.
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no statistical signiﬁcance between the 2 arms (27.7 months in the
geﬁtinib group vs 26.6 months in the chemotherapy group,
P = 0.483), likely explained by treatment crossover.83 The Japanese
phase III WJTOG3405 trial (N = 177) evaluated geﬁtinib vs cis-
platin/docetaxel in patients with EGFR-activating mutations. In thistrial, most patients had adenocarcinoma, 60% were women, and all
tested positive for EGFR mutations with the direct sequencing
method. Patients who received geﬁtinib had signiﬁcantly pro-
longed PFS compared with patients who received cisplatin/
docetaxel (9.2 vs 6.3 months, respectively).84 These results suggest
that geﬁtinib is superior to chemotherapy in terms of PFS and RR in
Table 3
Ongoing clinical trials evaluating EGFR TKIs as ﬁrst-line therapy in clinically and/or molecularly selected patient populations with advanced NSCLC.
Trial Estimated
enrollment
Patient population Therapy Estimated
completion
Primary endpoint(s)
Geﬁtinib
NCT00411047; phase II,
open-label
30 Female, adenocarcinoma histology,
non-smoker/former light smoker, or Asian
ethnicity
Geﬁtinib December 2012 RR
NCT01017874; phase III,
randomized, open-
label
226 Asian ethnicity and non-smoker/former light
smoker
Cisplatin/pemetrexed plus
geﬁtinib vs geﬁtinib
October 2014 PFS
NCT01203917; phase IV,
open-label
107 EGFR-activating mutations Geﬁtinib April 2014 RR
Erlotinib
NCT00126581; phase II,
randomized, open-
label
180 Adenocarcinoma and non-smoker/former
light smoker
Carboplatin/paclitaxel plus
erlotinib vs erlotinib
June 2010
(primary
completiona)
PFS
NCT00445848; phase II,
open-label
89 Adenocarcinoma and non-smoker Bevacizumab/erlotinib July 2013 OS
NCT01153984; phase II,
open-label
30 Adenocarcinoma and EGFR-activating
mutations
Erlotinib February 2015 PFS
NCT01260181; phase II,
open-label
30 EGFR-activating mutations Erlotinib October 2014 RR
NCT01250119; phase II,
open-label
120 EGFR exon 19 deletion or exon 21 mutation Erlotinib March 2013 Prevalence of EGFR
mutations at screening
NCT01310036; phase II,
open-label
208 EGFR-activating mutations Erlotinib December 2014 PFS
NCT00997334; phase II,
open-label
60 EGFR-activating mutations Erlotinib October 2012
(primary
completiona)
Frequency of mutations
conferring resistance
NCT00137839; phase II,
open-label
75 Female non-smokers or former light smokers
with adenocarcinoma
Erlotinib April 2013 RR
NCT01344824; phase II,
open-label
40 Non-smoker/former light smoker Carboplatin/pemetrexed
plus bevacizumab/
erlotinib
December 2015 PFS
NCT01131429; phase II,
randomized, open-
label
60 Adenocarcinoma and EGFR-activating
mutations
Cisplatin/docetaxel vs
erlotinib
June 2015 OS
NCT00661193; phase II,
randomized, open-
label
98 EGFR-activating mutations Carboplatin/paclitaxel plus
erlotinib vs erlotinib
October 2013
(primary
completiona)
PFS
NCT01342965; phase III,
randomized, open-
label
210 EGFR-activating mutations Cisplatin/gemcitabine vs
erlotinib
December 2013 PFS
NCT01287754; phase IV,
open-label
24 EGFR-activating mutations Erlotinib December 2015 PFS
Afatinib
NCT01121393; phase III,
randomized, open-
label
364 Adenocarcinoma and EGFR-activating
mutations
Cisplatin/gemcitabine vs
afatinib
May 2014 PFS
NCT00949650; phase III,
randomized, open-
label
330 Adenocarcinoma and EGFR-activating
mutations
Cisplatin/pemetrexed vs
afatinib
December 2013 PFS
Dacomitinib
NCT00818441; phase II,
open-label
114 Adenocarcinoma and non-smoker/former
light smoker or EGFR-activating mutations
Dacomitinib March 2015 PFS
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; NR, not reported; NSCLC, non-small cell lung cancer; OS, overall survival; PFS,
progression-free survival; RR, response rate; TKI, tyrosine kinase inhibitor.
a Refers to the ﬁnal data collection date for primary outcome measure; date that study will be completed in its entirety not speciﬁed on clinicaltrials.gov.
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Several phase II and phase III clinical trials are evaluating geﬁtinib
and other EGFR TKIs as ﬁrst-line therapy in clinically or molecu-
larly selected patients with advanced NSCLC (Table 3). Safety data
with geﬁtinib and other EGFR TKIs in molecularly selected patients
with NSCLC are summarized in Table 4.
Erlotinib (OSI-774)
Erlotinib is the only FDA-approved EGFR TKI in the United
States. It is only indicated for the treatment of patients with locally
advanced or metastatic NSCLC after failure of at least 1 priorchemotherapy regimen and for maintenance treatment in patients
whose disease has not progressed after 4 cycles of platinum-based
ﬁrst-line chemotherapy.85 In a recent multicenter, open-label, ran-
domized, phase III study (OPTIMAL; N = 165) comparing erlotinib
and gemcitabine/carboplatin chemotherapy as ﬁrst-line treatment
for patients with advanced EGFRmutation-positive NSCLC, a signif-
icant PFS beneﬁt (median 13.1 vs 4.6 months; HR, 0.16; 95% CI,
0.10–0.26; P < 0.0001) and more favorable tolerability were associ-
ated with erlotinib.86 In this trial, 86% of the patients had adeno-
carcinoma, 60% were women, 69% were never-smokers, and all
tested positive for EGFR mutation with the PCR method. The
European Erlotinib vs Chemotherapy (EURTAC; N = 174) trial was
Table 4
Grade 3/4 AE proﬁles of EGFR inhibitors in molecularly selected NSCLC patient populationsa.
Agent Source Reported grade 3/4 AEsb,c
Reversible EGFR inhibitors
Geﬁtinib WJTOG340584 ALT elevation (24%), AST elevation (14%), rash (2%), fatigue (2%), diarrhea (1%), nausea (1%), paronychia (1%), sensory disturbance (1%)
NEJ00282 Aminotransferase elevation (26%), appetite loss (5%), rash (5%), fatigue (3%), pneumonitis (3%), diarrhea (1%), arthralgia (1%),
neutropenia (1%)
Erlotinib OPTIMAL86 ALT elevation (4%), rash (2%), diarrhea (1%), stomatitis (1%), infection (1%)
EURTAC87 Rash (13%), fatigue (6%), diarrhea (5%), aminotransferase elevation (2%), neuropathy (1%), arthralgia (1%), pneumonitis (1%), anemia (1%)
Irreversible ErbB family inhibitors
Afatinib Yang et al88 Rash/acne (7% with 40 mg; 28% with 50 mg), diarrhea (7% with 40 mg; 22% with 50 mg)d
Dacomitinib Mok et al92 Diarrhea (15% with 45 mg; 0% with 30 mg), dermatitis acneiform (15% with 45 mg; 0% with 30 mg), stomatitis (3% with 45 mg; 0% with
30 mg)e
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
a Based on published phase III clinical trial data for reversible EGFR inhibitors in molecularly selected patients and available phase II clinical trial data for the irreversible
EGFR inhibitors.
b All grade P3 AEs reported.
c Incidence of AEs may vary by dose.
d Ranges reported correspond with 2 doses of afatinib (40 and 50 mg).
e Incidence of AEs reported for the 45-mg starting dose (0% incidences for each toxicity at the 30-mg starting dose).
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with platinum-based chemotherapy in chemonaive patients with
advanced NSCLC whose tumors had EGFR mutations. Among 173
patients evaluable at interim analysis, the difference in median
PFS (9.4 with erlotinib vs 5.2 months with chemotherapy; HR,
0.42; 95% CI, 0.27–0.64; P < 0.0001) was statistically signiﬁcant,
resulting in early closure of the trial.87 As shown in Table 2, ﬁnal
PFS and RR results favored erlotinib but there was no signiﬁcant
difference in median OS, although a high rate of crossover from
chemotherapy to EGFR TKIs (most commonly erlotinib) was noted.
Results from these 2 recent phase III clinical trials of erlotinib could
lead to approval of erlotinib in the ﬁrst-line setting for patients
with EGFR mutation-positive NSCLC.Afatinib (BIBW2992)
Afatinib is an irreversible TKI that might potentially overcome
the resistance of ﬁrst-generation EGFR TKIs. In preclinical studies,
afatinib has demonstrated activity against mutant EGFR in lung
cancer models.23 The phase II LUX-Lung 2 trial evaluated afatinib
in patients with advanced NSCLC whose tumors had EGFR muta-
tions and who were previously untreated or had received 1 prior
chemotherapy regimen.88 Among 129 patients who received afati-
nib as ﬁrst- or second-line treatment, median PFS was 10.1 months
(95% CI, 8.12–13.80 months) and median OS was 24.8 months (95%
CI, 21.98–38.74 months). Both PFS and OS were numerically longer
with ﬁrst-line treatment (12.0 months and not yet reached, respec-
tively) vs second-line treatment (8.0 months and 23.3 months,
respectively). Whereas median PFS was 13.7 months in patients
with deletion-19 mutations (12.0 months ﬁrst-line; 13.7 months
second-line) as well as in patients with L858R mutations
(15.6 months ﬁrst-line; 8.0 months second-line), it was 3.7 months
in patients with other mutations (4.5 months ﬁrst-line; 3.2 months
second-line). OS results followed a similar trend, with median
durations of 38.7 months for deletion-19 mutations (not reached
ﬁrst-line; 38.7 months second-line), 31.5 months for L858R muta-
tions (not reached ﬁrst-line; 23.3 months second-line), and
16.3 months for other mutations (15.5 months ﬁrst-line;
16.9 months second-line). LUX-Lung 3 (NCT00949650) is the larg-
est prospective trial in EGFR mutation-positive lung cancer evalu-
ating the efﬁcacy and safety of ﬁrst-line afatinib compared to
standard chemotherapy with cisplatin and pemetrexed. Prelimin-
ary data from LUX-Lung 3 show that ﬁrst-line afatinib signiﬁcantly
prolonged PFS vs standard chemotherapy (median 11.1 months vs
6.9 months with pemetrexed/cisplatin; HR, 0.58; P = 0.0004) andimproved the RR (56% vs 23%; P < 0.0001) with an associated delay
in worsening of lung cancer-related symptoms (cough [P = 0.0072]
and dyspnea [P = 0.0145]) in EGFR mutation-positive lung adeno-
carcinoma.89 LUX-Lung 6 (NCT01121393) is an ongoing phase III
trial that is evaluating the efﬁcacy and safety of ﬁrst-line afatinib
compared to the chemotherapy combination of cisplatin and gem-
citabine in molecularly selected patients (Table 3).Dacomitinib (PF-00299804)
The other ErbB family TKI dacomitinib has more attractive
pharmacokinetic properties compared with the ﬁrst-generation
irreversible pan-ErbB inhibitor CI-1033 (including greater bioavail-
ability, longer half-life, larger volume of distribution, and lower
clearance), and it has demonstrated preclinical activity in cancer
models with EGFR and ErbB2 mutations that are resistant to geﬁti-
nib.25,90,91 Dacomitinib has been evaluated in an ongoing phase II
study in patients with adenocarcinoma who were either non-
smokers/former light smokers or had documented EGFRmutations.
In a preliminary analysis of 27 patients with EGFR-activating muta-
tions, PFS rates at 4, 6, and 9 months were 95.7%, 84.7%, and 84.7%,
respectively.92 More recently, preliminary data were presented
speciﬁcally for 47 patients with exon 19 or 21 mutations, which in-
cluded a PR rate of 74%, 1-year PFS of 77%, and median PFS of
17 months (similar outcomes for each individual mutation).93Conclusion
It has been established that patients with advanced lung cancer
harboring EGFR-activating mutations are more likely to beneﬁt
from EGFR TKI therapy than patients with EGFR wild-type disease.
Although there is currently no consensus on the optimal EGFR
mutation detection method, technologies for identifying EGFR
mutations and other molecular markers are rapidly evolving. Based
on the activity of EGFR TKIs in clinically and/or molecularly se-
lected lung cancer patients, ongoing clinical trials are evaluating
EGFR and ErbB family inhibitors in these patients as ﬁrst-line ther-
apy. The results of these studies may help to determine the poten-
tial of these agents in the ﬁrst-line setting in NSCLC.Conﬂicts of interest statement
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